ArticleMicrobiology spectrum2023
Article in Microbiology spectrum, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- A systematic review of tetracyclines for nontuberculous mycobacteria: focus on rapidly growing mycobacteria.European respiratory review : an official journal of the European Respiratory Society · 2025Pooled it
- Eravacycline as a Novel Option for Treating Multidrug-Resistant Gram-Negative and Gram-Positive Bacterial Infections: A Narrative Review.Journal of clinical medicine · 2026Review
- The Rise in Carbapenem-ResistantPathogens (Basel, Switzerland) · 2026Review
- Copper ions restore antibacterial activity of tigecycline by regulating photodegradation pathway under light exposure.Communications biology · 2026Article
- In vitro and in vivo activity of eravacycline against Mycobacterium abscessus.BMC microbiology · 2026Article
- Eravacycline forMicrobiology spectrum · 2026Article
- Physical compatibility of omadacycline with intravenous agents used in the treatment of Mycobacteroides abscessus pulmonary disease.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2026Article
- Eravacycline: From broad-spectrum coverage to novel clinical applications.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026Review
- Performance of stool-based Xpert MTB/RIF assay in the diagnosis of presumptive pulmonary tuberculosis in adults unable to expectorate sputum.Microbiology spectrum · 2025Article
- In vitro Activity of the Novel Tetracyclines Derivative, Zifanocycline AgainstInfection and drug resistance · 2025Article
- Novel Synthetic Peptide Agelaia-12 Has Improved Activity AgainstPathogens (Basel, Switzerland) · 2024Article
- Omadacycline powder for research procured from unauthorized commercial vendors may be impure and/or unstable.Antimicrobial agents and chemotherapy · 2024Article
- Third-Generation Tetracyclines: Current Knowledge and Therapeutic Potential.Biomolecules · 2024Review
- Review
- Therapy ofMicroorganisms · 2024Review
- Long-term Safety and Tolerability of Omadacycline for the Treatment ofOpen forum infectious diseases · 2023Article
- Omadacycline, Eravacycline, and Tigecycline Express Anti-Mycobacterium abscessus ActivityMicrobiology spectrum · 2023Article
- Non-tuberculous mycobacterial disease: progress and advances in the development of novel candidate and repurposed drugs.Frontiers in cellular and infection microbiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infections caused by rapidly growing mycobacteria (RGM) have increased globally. Chemotherapy against these infections is challenging due to the minimal antimicrobial choices available. The main aim of this study was to evaluate the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.